Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

TODAY i have some great news to share. Besides the fact that last week was the King's Birthday, something exciting was happening in the HIV ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. Scientists say this ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk groups, as global HIV prevention efforts face funding setbacks ...

Key points Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show striking effectiveness across diverse populations at high risk for HIV.

The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...